Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENLOGA vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Treatment of urinary tract infections due to susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris,Treatment of acute otitis media in children,Treatment of acute exacerbations of chronic bronchitis in adults,Treatment of enteritis caused by Shigella flexneri or Shigella sonnei,Prophylaxis and treatment of Pneumocystis jirovecii pneumonia,Treatment of traveler's diarrhea,Treatment of toxoplasmosis
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
350 mg orally once daily with food.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (Cr Cl 30-50 m L/min)
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Sulfamethoxazole is primarily metabolized via N-acetylation (N-acetyltransferase 2) and glucuronidation. Trimethoprim is metabolized primarily by oxidative O-demethylation (CYP3A4, CYP1A2) and conjugation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
98% bound primarily to albumin
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
0.15-0.3 L/kg, indicating limited extravascular distribution
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 92% (high first-pass metabolism; extensive absorption)
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
GFR ≥45 m L/min: no adjustment; GFR 30-44 m L/min: 350 mg every other day; GFR <30 m L/min or ESRD: not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No specific dose adjustment recommended; monitor renal function closely in patients ≥65 years.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Fatal hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias have been reported with sulfonamides. JENLOGA is contraindicated in patients with a history of hypersensitivity to sulfonamides or trimethoprim.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Fatal hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash,Hematologic toxicity including agranulocytosis, aplastic anemia; monitor CBC regularly,Hepatic necrosis; discontinue if signs of liver injury occur,Severe renal impairment (Cr Cl <15 m L/min); avoid use,Potential for hyperkalemia in patients with renal dysfunction or those on potassium-sparing diuretics,Risk of folate deficiency; monitor folate levels in chronic therapy,Photosensitivity; avoid prolonged sun exposure
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Hypersensitivity to sulfonamides or trimethoprim,History of drug-induced immune thrombocytopenia with prior sulfonamides,Megaloblastic anemia due to folate deficiency,Severe renal impairment (Cr Cl <15 m L/min) unless for Pneumocystis jirovecii pneumonia treatment,Pregnancy at term and nursing mothers (due to potential for kernicterus in neonates),Concomitant use with dofetilide (increases risk of arrhythmias)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Take with or without food. High-fat meals may delay absorption but no significant clinical impact. Avoid grapefruit and grapefruit juice as they may alter drug levels.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-trimester exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal hypoglycemia.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Not recommended during breastfeeding. M/P ratio not established; drug is excreted in human milk. Potential for serious adverse reactions in nursing infants.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Dose adjustments required due to increased volume of distribution and enhanced clearance; monitor trough levels and adjust to maintain therapeutic range. Consider 30-50% dose increase in third trimester.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Jenloga (cenobamate) is a tetrazole-derived antiepileptic drug. Titrate slowly to reduce risk of severe hypersensitivity reactions, including DRESS syndrome. Monitor for QT shortening on ECG. Dose adjustments needed in renal impairment. Consider lower starting dose in patients with hepatic impairment.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take exactly as prescribed; do not stop suddenly without medical advice.,Report any rash, fever, or swollen lymph nodes immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception; drug may cause fetal harm.,Notify healthcare provider if you become pregnant or plan to.,May cause dizziness or somnolence; avoid driving until effects known.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENLOGA vs ALTAVERA, answered by our medical review team.
JENLOGA is a Oral Contraceptive that works by JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENLOGA and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENLOGA is: 350 mg orally once daily with food.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENLOGA and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENLOGA is classified as Category C. Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-tr. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.